EU/3/18/1986

Table of contents

About

On 22 February 2018, orphan designation (EU/3/18/1986) was granted by the European Commission to UCB Biopharma SPRL, Belgium, for seletalisib for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Key facts

Active substance
Seletalisib
Disease / condition
Treatment of activated phosphoinositide 3-kinase delta syndrome
Date of decision
22/02/2018
Outcome
Positive
Orphan decision number
EU/3/18/1986

Sponsor's contact details

UCB Biopharma SPRL
Allée de la Recherche 60
1070 Brussels
Belgium
Tel. +32-2-559 7481
E-mail: contactucb@ucb.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating